U.S. markets closed
  • S&P 500

    3,639.66
    -104.86 (-2.80%)
     
  • Dow 30

    29,296.79
    -630.15 (-2.11%)
     
  • Nasdaq

    10,652.40
    -420.91 (-3.80%)
     
  • Russell 2000

    1,702.15
    -50.36 (-2.87%)
     
  • Crude Oil

    93.20
    +4.75 (+5.37%)
     
  • Gold

    1,701.80
    -19.00 (-1.10%)
     
  • Silver

    20.16
    -0.50 (-2.42%)
     
  • EUR/USD

    0.9743
    -0.0052 (-0.54%)
     
  • 10-Yr Bond

    3.8830
    +0.0570 (+1.49%)
     
  • GBP/USD

    1.1098
    -0.0071 (-0.63%)
     
  • USD/JPY

    145.3300
    +0.2620 (+0.18%)
     
  • BTC-USD

    19,566.09
    -376.62 (-1.89%)
     
  • CMC Crypto 200

    445.50
    -9.53 (-2.09%)
     
  • FTSE 100

    6,991.09
    -6.18 (-0.09%)
     
  • Nikkei 225

    27,116.11
    -195.19 (-0.71%)
     

Editas Suddenly Terminates Chief Medical Officer Without An Explanation

·1 min read

Editas Medicine Inc (NASDAQ: EDIT) has fired Chief Medical Officer Lisa Michaels just 15 months into her tenure at the Company.

  • The biotech was mum on the reasoning for the termination, disclosed in a Securities and Exchange Commission filing.

  • The termination that occurred today is effective immediately.

  • According to the SEC filing, Michaels will receive her base salary for another 12 months.

  • Related: Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate.

  • RBC Capital Markets analyst called the news "incrementally negative" and wrote in a note that the firing "does not boost confidence" in a company with mixed clinical signals for LCA10 and high management turnover.

  • Analyst Luca Issi remains on the sidelines with a Sector Perform rating and $40 price target on Editas shares given what he views as mixed data for its lead asset, a "crowded" SCD space, and an oncology pipeline that remains early.

  • Price Action: EDIT shares are down 7.40% at $17.89 during the market session on the last check Tuesday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.